DTU Publications (2000-2009)

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.

Zinman B. et al, (2010), J Clin Endocrinol Metab, 95, 134 - 142

Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy

Nathan DM. et al, (2009), Diabetes Care, 32, 193 - 203

Perceptions of heart attack risk amongst individuals with diabetes.

Price HC. et al, (2009), Prim Care Diabetes, 3, 239 - 244

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

Control Group None. et al, (2009), Diabetologia, 52, 2288 - 2298

Three-year efficacy of complex insulin regimens in type 2 diabetes.

Holman RR. et al, (2009), N Engl J Med, 361, 1736 - 1747

Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses.

Lasserson DS. et al, (2009), Diabetologia, 52, 1990 - 2000

Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes.

Price HC. et al, (2009), Fam Pract, 26, 351 - 358

Presenting the results of clinical trials to participants.

Darbyshire JL. et al, (2009), Clin Med (Lond), 9, 415 - 416

International expert committee report on the role of the A1C assay in the diagnosis of diabetes

Nathan DM. et al, (2010), CPD Bulletin Clinical Biochemistry, 10, 25 - 33

Follow-up of intensive glucose control in type 2 diabetes.

Lund SS. et al, (2009), N Engl J Med, 360

Predicting 6-year mortality risk in patients with type 2 diabetes: response to Wells et al.

Paul S. et al, (2009), Diabetes Care, 32

Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort

Simmons RK. et al, (2008), DIABETOLOGIA, 51, S549 - S549

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?

Price HC. and Holman RR., (2009), Nat Clin Pract Cardiovasc Med, 6, 168 - 169

Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes.

Price HC. et al, (2009), Diabetologia, 52, 394 - 397

Blood glucose self-monitoring in type 2 diabetes: A randomised controlled trial

Farmer AJ. et al, (2009), Health Technology Assessment, 13

Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes.

Hartweg J. et al, (2009), Curr Opin Lipidol, 20, 30 - 38

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.

Holman RR. et al, (2009), Diabetologia, 52, 50 - 59

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan DM. et al, (2009), Diabetologia, 52, 17 - 30

10-year follow-up of intensive glucose control in type 2 diabetes.

Holman RR. et al, (2008), N Engl J Med, 359, 1577 - 1589

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

Holman RR. et al, (2008), N Engl J Med, 359, 1565 - 1576

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Califf RM. et al, (2008), Am Heart J, 156, 623 - 632

Determining the most appropriate components for a composite clinical trial outcome.

Bethel MA. et al, (2008), Am Heart J, 156, 633 - 640

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 x 2 factorial understanding risk trial.

Price HC. et al, (2008), Cardiovasc Diabetol, 7

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

DREAM Trial Investigators None. et al, (2008), Diabetes Care, 31, 1007 - 1014

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Kahn SE. et al, (2008), Diabetes Care, 31, 845 - 851

Addition of insulin to oral therapy in type 2 diabetes - Reply

Holman RR. et al, (2008), NEW ENGLAND JOURNAL OF MEDICINE, 358, 1198 - 1198

Clinical decisions. Management of type 2 diabetes.

Goldberg RB. et al, (2008), N Engl J Med, 358, 293 - 297

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

Nathan DM. et al, (2008), Diabetologia, 51, 8 - 11

Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78.

Cull CA. et al, (2007), Circulation, 116, 2119 - 2126

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

Holman RR. et al, (2007), N Engl J Med, 357, 1716 - 1730

Stability of soluble adhesion molecules, selectins, and C-reactive protein at various temperatures: implications for epidemiological and large-scale clinical studies.

Hartweg J. et al, (2007), Clin Chem, 53, 1858 - 1860

GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.

Desai M. et al, (2007), Diabetologia, 50, 2052 - 2060

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes.

Hartweg J. et al, (2007), Diabetologia, 50, 250 - 258

Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial.

Farmer A. et al, (2007), BMJ, 335

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.

Mount Hood 4 Modeling Group None., (2007), Diabetes Care, 30, 1638 - 1646

Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes.

Coleman RL. et al, (2007), Diabetes Care, 30, 1292 - 1293

An association analysis of the HLA gene region in latent autoimmune diabetes in adults.

Desai M. et al, (2007), Diabetologia, 50, 68 - 73

Metformin as first choice in oral diabetes treatment: the UKPDS experience.

Holman R., (2007), Journ Annu Diabetol Hotel Dieu, 13 - 20

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Kahn SE. et al, (2006), N Engl J Med, 355, 2427 - 2443

Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.

Wright AD. et al, (2006), J Diabetes Complications, 20, 395 - 401

Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36.

Clarke PM. et al, (2006), Diabetes Care, 29, 1506 - 1511

Risk factors for renal dysfunction in type 2 diabetes: U.K. (vol 55, pg 1832, 2006)

Retnakaran R. et al, (2011), DIABETES, 60, 1823 - 1823

The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults.

Desai M. et al, (2006), Diabetes, 55, 1890 - 1894

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

Holman RR., (2006), Metabolism, 55, S2 - S5

PROactive study.

Holman RR. et al, (2006), Lancet, 367, 25 - 26

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).

Stratton IM. et al, (2006), Diabetologia, 49, 1761 - 1769

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.

Viberti G. et al, (2006), Diabet Med, 23, 1289 - 1294

A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.

Davis TME. et al, (2006), Diabetes Care, 29

Effect of ramipril on the incidence of diabetes.

DREAM Trial Investigators None. et al, (2006), N Engl J Med, 355, 1551 - 1562

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators None. et al, (2006), Lancet, 368, 1096 - 1105

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan DM. et al, (2006), Diabetologia, 49, 1711 - 1721

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.

Kahn SE. et al, (2006), Diabetes, 55, 2357 - 2364

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.

Stettler C. et al, (2006), Am Heart J, 152, 27 - 38

Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study.

Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes.

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.

IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).

Erratum: IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) (Diabetologia (2005) 48 (703-708) DOI: http://dx.doi.org/10.1007/s00125-005-1691-9)

IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) (vol 48, pg 703, 2005)

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).

Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).

Framingham equations underestimate cardiovascular risk compared with the UKPDS risk engine in people with Type 2 diabetes

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.

Cull CA. et al, (2004), Diabet Med, 21, 1368 - 1371

Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.

Matthews DR. et al, (2004), Arch Ophthalmol, 122, 1631 - 1640

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

Clarke PM. et al, (2004), Diabetologia, 47, 1747 - 1759

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

Gerstein HC. et al, (2004), Diabetologia, 47, 1519 - 1527

A standardized triglyceride and carbohydrate challenge: the oral triglyceride tolerance test.

Mohanlal N. and Holman RR., (2004), Diabetes Care, 27, 89 - 94

A standardized triglyceride and carbohydrate challenge: response to Mohanlal and Holman.

Thanopoulou AC. et al, (2004), Diabetes Care, 27, 2092 - 2093

Comparative study of prognostic value for coronary disease risk between the U.K. Prospective diabetes study and framingham models: response to Protopsaltis et al.

Stevens RJ. and Holman R., (2004), Diabetes Care, 27, 1843 - 1844

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.

Stevens RJ. et al, (2004), Diabetes Care, 27, 201 - 207

Poor pregnancy outcome for women with Type 2 diabetes.

Hadden DR. et al, (2003), Diabet Med, 20, 506 - 507

The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).

Clarke P. et al, (2003), Diabet Med, 20, 442 - 450

Autoantibodies to the islet cell antigen SOX-13 are associated with duration but not type of diabetes.

Davis TME. et al, (2003), Diabet Med, 20, 198 - 204

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Adler AI. et al, (2003), Kidney Int, 63, 225 - 232

Fire-and-forget in prevention of coronary heart disease.

Karpe F. and Holman R., (2002), Lancet, 360

UKPDS58--modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.

Stevens RJ. et al, (2002), J Diabetes Complications, 16, 371 - 376

International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized trial.

Molyneux A. et al, (2002), J Stroke Cerebrovasc Dis, 11, 304 - 314

International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised trial

Molyneux A. et al, (2002), Lancet, 360, 1267 - 1274

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Viberti G. et al, (2002), Diabetes Care, 25, 1737 - 1743

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Homocysteine Studies Collaboration None., (2002), JAMA, 288, 2015 - 2022

Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.

Colagiuri S. et al, (2002), Diabetes Care, 25, 1410 - 1417

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

Clarke P. et al, (2002), Med Decis Making, 22, 340 - 349

UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.

Kothari V. et al, (2002), Stroke, 33, 1776 - 1781

Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors.

Grundy SM. et al, (2002), Circulation, 105, e153 - e158

A non-invasive frequent home blood glucose monitor

Lenzen H. et al, (2002), Practical Diabetes International, 19, 101 - 103

UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes.

Adler AI. et al, (2002), Diabetes Care, 25, 894 - 899

Human calcium/calmodulin-dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes.

Gloyn AL. et al, (2002), Diabetologia, 45, 580 - 583

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

Wright A. et al, (2002), Diabetes Care, 25, 330 - 336

Calculation of coronary risk in Type II diabetes: another cause for concern: authors' reply

Holman RR. et al, (2002), CLINICAL SCIENCE, 103, 219 - 219

The UKPDS: implications for the dyslipidaemic patient.

Holman R., (2001), Acta Diabetol, 38 Suppl 1, S9 - 14

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

Stevens RJ. et al, (2001), Clin Sci (Lond), 101, 671 - 679

Erratum: The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56) (Clinical Science (2001) 101 (671-679))

Stevens RI. et al, (2002), Clinical Science, 102

Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.

Clarke R. et al, (2001), J Cardiovasc Risk, 8, 363 - 369

Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.

Hashim Y. et al, (2001), Diabetologia, 44, 2227 - 2230

Butyrylcholinesterase K variant on chromosome 3q is associated with Type II diabetes in white Caucasian subjects (vol 44, pg 2227, 2001)

Hashim Y. et al, (2002), DIABETOLOGIA, 45, 459 - 459

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).

Davis TM. et al, (2001), Diabetes Care, 24, 1167 - 1174

An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).

Gray A. et al, (2001), Diabet Med, 18, 438 - 444

Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).

Kohner EM. et al, (2001), Diabet Med, 18, 178 - 184

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

Clarke P. et al, (2001), Diabetologia, 44, 298 - 304

UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.

Stratton IM. et al, (2001), Diabetologia, 44, 156 - 163

Possible prevention of type 2 diabetes with acarbose or metformin over three years

Citroen HA. et al, (2000), DIABETOLOGIA, 43, A73 - A73

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.

Neal B. et al, (2000), Lancet, 356, 1955 - 1964

Life-expectancy projection by modelling and computer simulation (UKPDS 46).

Stevens R. et al, (2000), Diabetes Res Clin Pract, 50 Suppl 3, S5 - 13

Seeing what you want to see in randomised controlled trials. Authors' choice of study was ill informed.

Holman R., (2000), BMJ, 321, 1078 - 1079

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

Adler AI. et al, (2000), BMJ, 321, 412 - 419

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

(2001), BMJ (Clinical research ed.), 322, 90 - 90

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Stratton IM. et al, (2000), BMJ, 321, 405 - 412

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)

Manley SE. et al, (2000), Diabetic Medicine, 17, 518 - 523

Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycemia?

Peacey SR. et al, (2000), Diabetes Care, 23, 1022 - 1023

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

Gray A. et al, (2000), BMJ, 320, 1373 - 1378